Akkermansia muciniphila supplementation has been shown to reduce BP through the reduction of OS markers, likely through increased propionate production, but its translation to the clinic is quite controversial (Lakshmanan et al., 2022)
By increasing insulin release after meals, Ozempic helps lower blood glucose levels
Liou et al., 1997
Nonetheless it has been demonstrated that colostrum exhibits higher levels of immunological components in comparison to mature milk [12, 13]
23,33 environ 70 ml Avantages Dtails du produit Reviews (0) 6 Produits No reviews Les clients qui ont achet ce produit ont galement achet : Disponible Crme et pommade Fair&White crme claircissante 6,25 50 ml Pour peaux noires retrouvez un teint unifi et lumineux sans hydroquinone Rupture de stock Disponible
RCT STEP 9 - Semaglutide vs Placebo for Knee Osteoarthritis in Patients with Obesity, NEJM (2024) [PubMed abstract] The STEP 9 study enrolled 407 patients with BMI 30 and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain Main inclusion criteria Age 18 years or older BMI 30 ACR diagnostic criteria for knee OA Moderate X-ray changes (Kellgren-Lawrence grade 2 or 3) in target knee Knee OA WOMAC pain score of 40 Main exclusion criteria Use of opioid medications Use of obesity medication within 90 days Knee injection within 90 days Baseline characteristics Average age - 56 years Average weight - 239 lbs (108.6 kg) Average BMI - 40.3 Female sex - 82% Average WOMAC pain score - 70.9 Randomized treatment groups Group 1 (271 patients): Semaglutide 2.4 mg once weekly Group 2 (136 patients): Placebo Semaglutide was started at 0.24 mg once weekly and titrated over 16 weeks to 2.4 mg The percentage change in body weight and the change in the WOMAC pain score (scale 0 - 100, with higher scores meaning worse outcomes) from baseline to week 68 Primary outcome: Results Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo
